CD8A and neoplasm: To extend our concept, we combined the PLGA-NP-based therapeutic vaccine system with tumor antigens and adjuvants.19 20 This approach was selected because of the increased efficiency of intracellular delivery of tumor antigens and adjuvants to DCs, induction of DC maturation, and activation of cytotoxic CD8+ T cells via antigen-specific cross-presentation, leading to increased tumor-specific cytotoxic CD8+ T cell responses.